MSN Home  |  My MSN  |  Hotmail
Sign in to Windows Live ID Web Search:   
go to MSNGroups 
Free Forum Hosting
 

Important Announcement Important Announcement
The MSN Groups service will close in February 2009. You can move your group to Multiply, MSN’s partner for online groups. Learn More
Friends With RSD/Chronic Pain And Illnesses[email protected] 
  
What's New
  
  Messages  
  ♥.·:*¨¨*:·.♥.·:*:·.♥.·:*¨¨*:·.♥  
  General  
  Games  
  Church Services  
  ♥.·:*¨¨*:·.♥.·:*:·.♥.·:*¨¨*:·.♥  
  Health Center  
  
  Arthritis  
  
  Back&neck Pain  
  
  Cancer  
  
  Caregiving  
  
  Chronic Ilnness  
  
  Diabetes  
  
  Depression&anxie  
  
  Fibromyalgia  
  
  Health Tips  
  
  Lupus/Autoimmune  
  
  Medication  
  
  Misc. Medical  
  
  MS  
  
  Neurological  
  
  Pain Information  
  
  Rare Diseases  
  
  RSD/CRPS  
  ♥.·:*¨¨*:·.♥.·:*:·.♥.·:*¨¨*:·.♥  
  Help Center  
  ♥.·:*¨¨*:·.♥.·:*:·.♥.·:*¨¨*:·.♥  
  Drug Assist Programs  
  ♥.·:*¨¨*:·.♥.·:*:·.♥.·:*¨¨*:·.♥  
  Dept. Of Aging&Adult Services  
  ♥.·:*¨¨*:·.♥.·:*:·.♥.·:*¨¨*:·.♥  
  Backgrounds 4 Use  
  ♥.·:*¨¨*:·.♥.·:*:·.♥.·:*¨¨*:·.♥  
  Pictures  
  Links  
  ♥.·:*¨¨*:·.♥.·:*:·.♥.·:*¨¨*:·.♥  
  
  
  Tools  
 
Lupus/Autoimmune : Prevention of vascular damage in scleroderma
Choose another message board
 
     
Reply
 Message 1 of 1 in Discussion 
From: MSN Nicknamepray4acure2  (Original Message)Sent: 1/3/2008 8:34 PM

Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril.

University of Wales, Bangor, UK.

OBJECTIVE: To evaluate the efficacy and tolerability of prolonged administration of quinapril, a long-acting angiotensin-converting enzyme inhibitor, in the management of the peripheral vascular manifestations of limited cutaneous systemic sclerosis (lcSSc) and in the prevention of the progression of visceral organ involvement in the disease. METHODS: This was a multicenter, randomized, double-blind, placebo-controlled study evaluating quinapril 80 mg/day, or the maximum tolerated dosage, in 210 patients with lcSSc or with Raynaud's phenomenon (RP) and the presence of SSc-specific antinuclear antibodies. Treatment was for 2-3 years. The primary outcome measure was the number of new ischemic ulcers appearing on the hands; secondary measures were the frequency and severity of RP attacks, skin score, treatments for ischemia, health status (measured by the Short Form 36 instrument), measures of kidney and lung function, and echocardiographic estimates of pulmonary artery pressure. An intent-to-treat analysis was used. RESULTS: Quinapril did not affect the occurrence of digital ulcers or the frequency or severity of RP episodes. It did not alter the treatments that were prescribed for either infected ulcers or severe RP symptoms. There was no apparent effect on the estimated tricuspid gradient. Health status was not affected by quinapril, and one-half of the patients who believed they had benefited from the trial treatment were in the placebo arm. Quinapril was not tolerated by one-fifth of the patients, with dry cough being the most frequent side effect. CONCLUSION: Administration of quinapril for up to 3 years had no demonstrable effects on the occurrence of upper limb digital ulcers or on other vascular manifestations of lcSSc in this patient population.

PMID: 17968938 [PubMed - indexed for MEDLINE]



First  Previous  No Replies  Next  Last